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The global burden of disease from ambient air 
pollution is substantial (nearly 8% of all deaths), 
and increasing with time—largely due to increases 
in fine particulate matter (PM2·5) and the number of 
deaths from non-communicable diseases, especially 
in large low-income and middle-income countries 
(LMICs) experiencing population growth and ageing.1 
Increased awareness of air pollution as a major global 
public health issue is reflected in the inclusion of air 
pollution-related mortality and morbidity in targets 
to meet the health-focused Sustainable Development 
Goal 3. Despite the large burden of disease from 
ambient air pollution and evidence of the cost-
effectiveness of mitigation measures,2 surprisingly 
it remains largely absent from guidance on non-
communicable disease prevention.3
The body of epidemiological evidence regarding 
the health effects of air pollution is now large; 
evidence has emerged that air pollution is associated 
with every major organ system.4 Nonetheless, the 
evidence is conspicuously incomplete; a point clearly 
illustrated by the systematic review and meta-analysis 
by Katherine Newell and colleagues5 of the effects of 
particulate matter (PM10 and PM2·5) on cardiovascular 
and respiratory mortality and hospital admissions. 
Previous systematic reviews have yielded convincing 
evidence of the effect of short-term exposure to 
particulate matter on cardiorespiratory mortality 
and hospital admissions, including for myocardial 
infarction, heart failure, and stroke.6–8 Newell and 
colleagues add to the scientific literature by focusing 
specifically on LMICs and potential variations in 
magnitude across LMIC regions.
The most notable finding from the systematic review 
is the very small number of studies of long-term 
exposure. Of 91 studies meeting the eligibility criteria, 
only four were studies of long-term exposure derived 
from two Chinese populations, providing estimates 
based on PM10 but not PM2·5. The meta-analysis 
included only studies relating day-to-day variation in 
air pollution and daily counts of deaths and hospital 
admissions from time-series and case-crossover studies. 
Among the studies included in the meta-analysis, only 
one was available for Africa. In cases for which enough 
studies were available to compare estimates between 
LMIC regions, estimates were larger for Latin America 
and the Caribbean compared with east Asia and the 
Pacific for several outcomes, including respiratory and 
stroke mortality. Whether observed differences in effects 
are due to differences in particle concentrations or 
composition, population vulnerability, or cause of death 
determination across countries is unclear and warrants 
further research.
This systematic review5 brings the paucity of 
studies linking long-term exposure to PM2·5 and 
cardiorespiratory mortality and morbidity at exposure 
levels above those seen in North American and 
western Europe into sharp focus. This paucity of 
research in LMICs is one of the main limitations in the 
evolving Global Burden of Disease effort to estimate 
attributable burdens to air pollution.1 At present, 
the Global Burden of Disease estimates for PM2·5 are 
based on integrated exposure response functions 
combining estimates from cohort studies of long-term 
exposure in high-income countries (with relatively 
low exposures) with passive and active smoking to 
approximate the global exposure range.9 A clear need 
exists for more direct epidemiological evidence of 
long-term exposure at high pollution levels in view of 
the high likelihood that relationships are not linear. 
Estimates from short-term exposure studies, such 
as those included in the meta-analysis by Newell 
and colleagues, shed limited light on the burden of 
disease in LMICs because the effects from short-term 
exposures are smaller than the effects from long-term 
exposures,10 resulting in an underestimation of the full 
effect of air pollution on cardiorespiratory health.
Filling this gap in the epidemiological evidence 
will require advances in the estimation of long-term 
exposure to particulates in LMICs. Substantial challenges 
remain in the adaptation of exposure models used for 
large population studies in high-income countries to 
LMIC settings. Ambient monitoring is less available 
in LMICs than in high-income countries, and what is 
available, rarely covers rural areas. Additionally, LMICs 
tend to have greater diversity of local sources of air 
pollution (eg, crop and trash burning, biomass-fuel 
use, and culturally specific sources), which are difficult 
to capture with routinely available land-use or remote-
sensing data.
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Present knowledge suggests the relation between 
particulate matter and cardiovascular and respiratory 
mortality flattens out at higher exposure levels.1 The 
systematic review by Newell and colleagues5 covered 
cities with mean PM2·5 levels ranging from 56 µg/m³ to 
179 µg/m³ (43–142 µg/m³ for PM10). The authors could 
have taken their analysis further to investigate the 
shape of the exposure–response relationship over this 
broad range, shedding light on the extent to which 
mean concentration contributed to the substantial 
heterogeneity reported across studies.
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